Condition: Gastrointestinal Stromal Tumors · Sponsor: Asan Medical Center
In this study, the investigators aim to investigate the efficacy and safety of 5 years of adjuvant imatinib treatment in patients with tumor rupture defined by Nishida classification or those with a tumor size 10cm or larger and a mitotic index of 10/50HPFs or higher.
This description comes directly from the study's public registry record.
Ryu Min-Hee, MD, PhD · 82-2-3010-5936 · miniryu@amc.seoul.kr
Kang Yoon-Koo, MD, PhD · 82-2-3010-3230 · ykkang@amc.seoul.kr
Always discuss trial participation with your own doctor first.
| Asan Medical Center, University of Ulsan College of Medicine | Seoul, Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05385549